ACLX Q3 2024 Earnings — Arcellx, Inc. Revenue & Financial Results | Market Cap Arena

ACLXArcellx, Inc.

$7B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+74.0% YoY

Gross Profit

$26M100.0% margin

Operating Income

-$34M-129.1% margin

Net Income

-$26M-99.4% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

-4.9%

Cash Flow

Operating Cash Flow

$31M

Free Cash Flow

$28M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$765M

Total Liabilities

$282M

Stockholders' Equity

$483M

Cash & Equivalents

$162M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$15M	+74.0%
Gross Profit	$26M	$15M	+79.4%
Operating Income	-$34M	-$45M	+25.1%
Net Income	-$26M	-$39M	+34.2%